vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and TIC Solutions, Inc. (TIC). Click either name above to swap in a different company.
TIC Solutions, Inc. is the larger business by last-quarter revenue ($508.3M vs $346.4M, roughly 1.5× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs -9.3%, a 37.4% gap on every dollar of revenue. HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $37.1M).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
HAE vs TIC — Head-to-Head
Income Statement — Q4 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $346.4M | $508.3M |
| Net Profit | $97.3M | $-47.2M |
| Gross Margin | 57.2% | 35.2% |
| Operating Margin | 36.1% | -3.8% |
| Net Margin | 28.1% | -9.3% |
| Revenue YoY | 4.8% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $346.4M | — | ||
| Q4 25 | $339.0M | $508.3M | ||
| Q3 25 | $327.3M | $473.9M | ||
| Q2 25 | $321.4M | $313.9M | ||
| Q1 25 | $330.6M | $234.2M | ||
| Q4 24 | $348.5M | — | ||
| Q3 24 | $345.5M | — | ||
| Q2 24 | $336.2M | — |
| Q1 26 | $97.3M | — | ||
| Q4 25 | $44.7M | $-47.2M | ||
| Q3 25 | $38.7M | $-13.9M | ||
| Q2 25 | $34.0M | $-233.0K | ||
| Q1 25 | $58.0M | $-25.8M | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $33.8M | — | ||
| Q2 24 | $38.4M | — |
| Q1 26 | 57.2% | — | ||
| Q4 25 | 59.7% | 35.2% | ||
| Q3 25 | 59.5% | 32.2% | ||
| Q2 25 | 59.8% | 23.6% | ||
| Q1 25 | 58.4% | 18.6% | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — |
| Q1 26 | 36.1% | — | ||
| Q4 25 | 19.9% | -3.8% | ||
| Q3 25 | 17.9% | -1.4% | ||
| Q2 25 | 16.8% | 5.8% | ||
| Q1 25 | 21.6% | -4.0% | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 11.8% | — |
| Q1 26 | 28.1% | — | ||
| Q4 25 | 13.2% | -9.3% | ||
| Q3 25 | 11.8% | -2.9% | ||
| Q2 25 | 10.6% | -0.1% | ||
| Q1 25 | 17.5% | -11.0% | ||
| Q4 24 | 10.8% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | 11.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | $0.95 | — | ||
| Q3 25 | $0.81 | $-0.08 | ||
| Q2 25 | $0.70 | — | ||
| Q1 25 | $1.17 | — | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.66 | — | ||
| Q2 24 | $0.74 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $245.4M | $439.5M |
| Total DebtLower is stronger | $1.2B | $1.6B |
| Stockholders' EquityBook value | $796.3M | $2.2B |
| Total Assets | $2.4B | $4.4B |
| Debt / EquityLower = less leverage | 1.53× | 0.74× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $245.4M | — | ||
| Q4 25 | $363.4M | $439.5M | ||
| Q3 25 | $296.4M | $164.4M | ||
| Q2 25 | $292.9M | $130.1M | ||
| Q1 25 | $306.8M | $155.7M | ||
| Q4 24 | $320.8M | — | ||
| Q3 24 | $299.3M | — | ||
| Q2 24 | $344.4M | — |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $1.6B | ||
| Q3 25 | $1.2B | $1.6B | ||
| Q2 25 | $1.2B | $751.3M | ||
| Q1 25 | $1.2B | $752.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $796.3M | — | ||
| Q4 25 | $911.5M | $2.2B | ||
| Q3 25 | $849.2M | $2.0B | ||
| Q2 25 | $882.3M | $1.2B | ||
| Q1 25 | $820.8M | $1.1B | ||
| Q4 24 | $906.9M | — | ||
| Q3 24 | $878.9M | — | ||
| Q2 24 | $905.4M | — |
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.5B | $4.4B | ||
| Q3 25 | $2.4B | $4.2B | ||
| Q2 25 | $2.5B | $2.2B | ||
| Q1 25 | $2.5B | $2.2B | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.34× | 0.74× | ||
| Q3 25 | 1.44× | 0.83× | ||
| Q2 25 | 1.39× | 0.64× | ||
| Q1 25 | 1.49× | 0.67× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $293.2M | $49.7M |
| Free Cash FlowOCF − Capex | $209.9M | $37.1M |
| FCF MarginFCF / Revenue | 60.6% | 7.3% |
| Capex IntensityCapex / Revenue | 9.5% | 2.5% |
| Cash ConversionOCF / Net Profit | 3.01× | — |
| TTM Free Cash FlowTrailing 4 quarters | $417.1M | $61.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $293.2M | — | ||
| Q4 25 | $93.6M | $49.7M | ||
| Q3 25 | $111.3M | $19.0M | ||
| Q2 25 | $17.4M | $-6.5M | ||
| Q1 25 | $116.6M | $32.8M | ||
| Q4 24 | $43.8M | — | ||
| Q3 24 | $48.8M | — | ||
| Q2 24 | $-27.4M | — |
| Q1 26 | $209.9M | — | ||
| Q4 25 | $87.2M | $37.1M | ||
| Q3 25 | $106.3M | $10.3M | ||
| Q2 25 | $13.6M | $-14.5M | ||
| Q1 25 | $100.9M | $28.3M | ||
| Q4 24 | $35.2M | — | ||
| Q3 24 | $39.4M | — | ||
| Q2 24 | $-33.1M | — |
| Q1 26 | 60.6% | — | ||
| Q4 25 | 25.7% | 7.3% | ||
| Q3 25 | 32.5% | 2.2% | ||
| Q2 25 | 4.2% | -4.6% | ||
| Q1 25 | 30.5% | 12.1% | ||
| Q4 24 | 10.1% | — | ||
| Q3 24 | 11.4% | — | ||
| Q2 24 | -9.8% | — |
| Q1 26 | 9.5% | — | ||
| Q4 25 | 1.9% | 2.5% | ||
| Q3 25 | 1.5% | 1.8% | ||
| Q2 25 | 1.2% | 2.6% | ||
| Q1 25 | 4.7% | 1.9% | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 1.7% | — |
| Q1 26 | 3.01× | — | ||
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
TIC
| Consulting Engineering Segment | $300.1M | 59% |
| Geospatial Segment | $131.3M | 26% |
| Fixed Unit Price Contracts | $54.3M | 11% |
| Other | $22.6M | 4% |
